Treatment of cognitive dysfunction in major depressive disorder-a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine

被引:64
|
作者
Pehrson, Alan L. [1 ]
Leiser, Steven C. [2 ]
Gulinello, Maria [3 ]
Dale, Elena [2 ]
Li, Yan [1 ]
Waller, Jessica A. [1 ]
Sanchez, Connie [1 ]
机构
[1] Lundbeck Res USA Inc, External Sourcing & Sci Excellence, Paramus, NJ 07652 USA
[2] Landbeck Res USA Inc, Bioanal & Physiol, Paramus, NJ 07652 USA
[3] Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA
关键词
Major depressive disorder; Cognitive function; Vortioxetine; Lu AA21004; Electrophysiology; Receptor occupancy; MEDIAL PREFRONTAL CORTEX; CHRONIC MILD STRESS; ADULT HIPPOCAMPAL NEUROGENESIS; ELDERLY GENERAL-POPULATION; ACUTE TRYPTOPHAN DEPLETION; LU AA21004; SYNAPTIC PLASTICITY; ALZHEIMERS-DISEASE; QUANTITATIVE EEG; TREATMENT INCREASES;
D O I
10.1016/j.ejphar.2014.07.044
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Although major depressive disorder is primarily considered a mood disorder, depressed patients commonly present with clinically significant cognitive dysfunction that may add to their functional disability. This review paper summarizes the available preclinical data on the effects of antidepressants, including monoamine reuptake inhibitors and the multimodal antidepressant vortioxetine, in behavioral tests of cognition such as cognitive flexibility, attention, and memory, or in potentially cognition-relevant mechanistic assays such as electroencephalography, in vivo microdialysis, in vivo or in vitro electrophysiology, and molecular assays related to neurogenesis or synaptic sprouting. The available data are discussed in context with clinically relevant doses and their relationship to target occupancy levels, in order to evaluate the translational relevance of preclinical doses used during testing. We conclude that there is preclinical evidence suggesting that traditional treatment with monoamine reuptake inhibitors can induce improved cognitive function, for example in cognitive flexibility and memory, and that the multimodal-acting antidepressant vortioxetine may have some advantages by comparison to these treatments. However, the translational value of the reviewed preclinical data can be questioned at times, due to the use of doses outside the therapeutically-relevant range, the lack of data on target engagement or exposure, the tendency to investigate acute rather than long term antidepressant administration, and the trend towards using normal rodents rather than models with translational relevance for depression. Finally, several suggestions are made for advancing this field, including expanded use of target occupancy assessments in preclinical and clinical experiments, and the use of translationally valuable techniques such as electroencephalography. (C) 2014 The Authors. Published by Elsevier B.V.
引用
收藏
页码:19 / 31
页数:13
相关论文
共 39 条
  • [11] A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder
    Papakostas, George I.
    Fava, Maurizio
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2006, 51 (12): : 783 - 790
  • [12] Selective serotonin reuptake inhibitors in major depression disorder treatment: an umbrella review on systematic reviews
    Darab, Mohsen Ghaffari
    Hedayati, Arvin
    Khorasani, Elahe
    Bayati, Mohsen
    Keshavarz, Khosro
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2020, 24 (04) : 357 - 370
  • [13] Salivary cortisol in women with major depressive disorder under selective serotonin reuptake inhibitors therapy
    Ewelina Dziurkowska
    Marek Wesolowski
    Maciej Dziurkowski
    Archives of Women's Mental Health, 2013, 16 : 139 - 147
  • [14] Salivary cortisol in women with major depressive disorder under selective serotonin reuptake inhibitors therapy
    Dziurkowska, Ewelina
    Wesolowski, Marek
    Dziurkowski, Maciej
    ARCHIVES OF WOMENS MENTAL HEALTH, 2013, 16 (02) : 139 - 147
  • [15] Hyponatremia associated with selective serotonin reuptake inhibitors, mirtazapine and venlafaxine, in Korean patients with major depressive disorder
    Jung, Y. -E.
    Jun, T. -Y.
    Kim, K. -S.
    Bahk, W. -M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2011, 49 (07) : 437 - 443
  • [16] Selective Serotonin Reuptake Inhibitors for Cessation of Betel Quid Use in Patients with Major Depressive Disorder in Taiwan
    Hung, Chung-Chieh
    Tu, Hung-Pin
    Chung, Chia-Min
    BIOMEDICINES, 2024, 12 (11)
  • [17] Evaluation of the effect of selective serotonin-reuptake inhibitors on lymphocyte subsets in patients with a major depressive disorder
    Eugenia Hernandez, Maria
    Martinez-Fong, Daniel
    Perez-Tapia, Mayra
    Estrada-Garcia, Iris
    Estrada-Parra, Sergio
    Pavon, Lenin
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 (02) : 88 - 95
  • [18] Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: Analysis of patients beginning adjunctive treatment in a 52-week, open-label study
    Clayton A.H.
    Baker R.A.
    Sheehan J.J.
    Cain Z.J.
    Forbes R.A.
    Marler S.V.
    Marcus R.
    Berman R.M.
    Thase M.E.
    BMC Research Notes, 7 (1)
  • [19] Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors
    Cooper-Kazaz, Rena
    Lerer, Bernard
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 (05) : 685 - 699
  • [20] The effect of selective serotonin reuptake inhibitors in healthy first-degree relatives of patients with major depressive disorder
    Knorr, Ulla Benedichte
    DANISH MEDICAL JOURNAL, 2012, 59 (04):